EIR Biopharma ^{Filed Terms, NYSE American: EIRB.RC}

We are an early-stage biopharmaceutical company focused on developing therapeutics for the treatment of eye disease. Combined, our founders have more than 50 years of senior level management experience in the biotechnology, pharmaceutical, and biopharma industries, including leadership roles at Intercept Pharmaceuticals, Iovance Biotherapeutics, and GT Biopharma. Our strategy is to negotiate worldwide exclusive licenses for the right to develop therapies for the treatment of eye disease; we target preclinical assets that promise to meet clear clinical needs and that can be advanced to a clinical stage with the investment of several million dollars over 14 to 18 months. Our principal preclinical assets have been licensed from prominent research institutions, including the Weill Cornell Medical College of Cornell University and the University of Miami. EIR-0205 is a small molecule drug we licensed from Cornell University that we intend to develop for treatment of the atrophic “dry” form of age-related macular degeneration (dry AMD). EIR-0205 is a functionalized cyclodextrin designed to extract lipofuscin, a waste product that accumulates in the retinal epithelium causing degeneration of the retina leading to dry AMD. We are currently soliciting proposals from CROs for the activities necessary to enable submission of an Investigational New Drug (IND) application with the FDA.